newsfilter
← Latest News
GlobeNewswire·

Vaccitech's VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T cells against targeted hepatitis B viral antigens. C